CRMD News and Press, CorMedix Inc. From 06/15/23

BERKELEY HEIGHTS, N.J. , June 15, 2023 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening diseases and conditions, today announced its first-of-kind strat...

BERKELEY HEIGHTS, N.J., May 30, 2023 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases, today announced that management will ...

2023-05-16 10:13:55 ET CorMedix Inc. ( NASDAQ: CRMD ) announced Tuesday that the company resubmitted its marketing application for lead product candidate DefenCath targeted at reducing the risk of catheter-related infection in kidney disease patients on hemodialysis. The Berke...

BERKELEY HEIGHTS, N.J., May 16, 2023 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening diseases and conditions, today announced that the New Drug Applica...

2023-05-15 22:30:24 ET Image source: The Motley Fool. CorMedix (NASDAQ: CRMD) Q1 2023 Earnings Call May 15, 2023 , 4:30 p.m. ET Operator Continue reading For further details see: CorMedix (CRMD) Q1 2023 Earnings Call Transcript

2023-05-15 19:27:03 ET CorMedix Inc. (CRMD) Q1 2023 Earnings Call May 15, 2023 4:30 PM ET Company Participants Joe Todisco - Chief Executive Officer Matt David - Executive Vice President and Chief Financial Officer Phoebe Mounts - Executive Vice President and Gen...

2023-05-15 16:12:57 ET CorMedix press release ( NASDAQ: CRMD ): Q1 GAAP EPS of -$0.24 misses by $0.04 . Cash and short-term investments, excluding restricted cash, at March 31, 2023 amounted to $55.6 million. For further details see: CorMedix GAAP EPS of -$0....

BERKELEY HEIGHTS, N.J., May 15, 2023 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening diseases and conditions, today announced financial results for the...

2023-05-14 17:35:54 ET Major earnings expected after the bell on Monday include: Danaos Corporation ( DAC ) Canoo ( GOEV ) Arrival ( ARVL ) Cara Therapeutics ( CARA ) Fortuna Silver Mines ( FSM ) For further details see: Notable earnings a...

2023-05-14 17:35:00 ET CorMedix ( NASDAQ: CRMD ) is scheduled to announce Q1 earnings results on Monday, May 15th, after market close. The consensus EPS Estimate is -$0.20 Over the last 3 months, EPS estimates have seen 1 upward revision and 0 downward. For f...